Sincrolab builds gamified, AI-driven digital cognitive training and rehabilitation platforms aimed at treating cognitive deficits across populations including children with ADHD and adults with mild cognitive impairment or age-related decline. Its system personalizes treatment by automatically adjusting exercise difficulty, generating automated reports for healthcare professionals, and tailoring programs to individual patient profiles. The company has demonstrated clinical evidence in Spanish placebo-controlled trials, reporting superior efficacy versus placebo with about 54% of ADHD participants achieving clinically significant improvements after 12 weeks. Sincrolab has obtained CE Class IIa certification for its digital ADHD solution and claims adoption by more than 800 therapists, over 100 healthcare centers, and tens of thousands of cognitive training sessions. Backed by over a decade of development, the company offers both pediatric and adult versions of its application and is pursuing broader clinical deployment and international market expansion. Recent investment support from Eoniq.fund is intended to strengthen its AI engine, scale infrastructure, and accelerate partnerships and institutional adoption.

Total raised

$0M

Funding rounds

1

Latest round

Equity

Latest activity

Jun 2026